🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kenan Gu

National Institutes of Health

ORCID: 0009-0001-9621-8439

Also affiliated with National Institute of Allergy and Infectious Diseases

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis”.

Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.01312-22

N/A

0.406DataRank · unranked

14 citations

C. Buddy Creech, Nan Wu, Roger L. Nation, Kenan Gu, Demet Nalbant +10 more

Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients

Journal of Antimicrobial Chemotherapy(2023)10.1093/jac/dkad106

N/A

0.330DataRank · unranked

8 citations

C. Buddy Creech, Nan Wu, Roger L. Nation, Kenan Gu, Demet Nalbant +10 more

Population Pharmacokinetics of Meropenem Across the Adult Lifespan

Clinical Pharmacokinetics(2024)10.1007/s40262-024-01465-1

N/A

0.241DataRank · unranked

4 citations

Stephen J. Balevic, Marion Hemmersbach‐Miller, Patricia Winokur, Kenan Gu, Austin W. Chan +9 more

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Clinical and Translational Science(2022)10.1111/cts.13286

N/A

0.241DataRank · unranked

4 citations

Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang, Taylor Sandison +2 more

Evaluation of the safety profile and intrapulmonary pharmacokinetics of intravenous fosfomycin in healthy adults

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.01395-24

N/A

0.227DataRank · unranked

3 citations

Zhonghui Yang, Stephen P. Bergin, Robert M. Tighe, Emily Randolph, B. Hauser +7 more

Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae451

N/A

0DataRank · unranked

5 citations

Andrew G. Sokolow, Pratish C Patel, Katherine Sokolow, Natalia Jimenez‐Truque, William H. Fissell +12 more

Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598

Medical Mycology(2024)10.1093/mmy/myae032

N/A

0DataRank · unranked

11 citations

Robert W. Spitz, Erin Hammett, Anna Jaunarajs, Varduhi Ghazaryan, Edward P. Garvey +2 more

Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients

Critical Care Explorations(2024)10.1097/cce.0000000000001159

N/A

0DataRank · unranked

3 citations

Omayma A. Kishk, Adnan Bhutta, Ginny E. Cummings, Hana M. El Sahly, Manpreet Virk +11 more

Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan

Clinical Pharmacokinetics(2023)10.1007/s40262-022-01198-z

N/A

0DataRank · unranked

12 citations

Stephen J. Balevic, Patricia Winokur, Cornelia B. Landersdorfer, Kenan Gu, Austin W. Chan +8 more